Dr. Jarushka Naidoo is a Consultant Medical Oncologist at Beaumont Hospital, Dublin (Ireland) and an Adjunct Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Center for Cancer Immunotherapy, at Johns Hopkins University, in Baltimore, MD. Dr. Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed both internal medicine training and a medical oncology fellowship through the Royal College of Physicians of Ireland. She then completed an awarded advanced fellowship at Memorial Sloan Kettering Cancer Center (New York), and joined the faculty at Johns Hopkins University in 2015. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related adverse events, and was the co-chair of the multidisciplinary Johns Hopkins Immune-related Toxicity Team. She recently returned to Ireland to lead the lung cancer program at Beaumont Hospital (Dublin) and the Royal College of Surgeons of Ireland. She will also serve as the new chair of the thoracic committee for Cancer Trials Ireland, where she will direct and lead the national clinical trial program for lung and thoracic cancers. Dr. Naidoo currently leads investigator-initiated trials for patients with lung cancer, specifically for those with stage III non-small lung cancer, and those with CNS metastases. She is the Chair of the Immunotherapy Subcommittee of the NRG Clinical Trials Cooperative Group and serves on the ASCO and SITC Immune-Related Toxicity Guideline Panels. She is the recipient of several grants and awards.

Dr. Misako Nagasaka is a thoracic oncologist and a clinical investigator at the Karmanos Cancer Institute, located in Detroit, Michigan. She is also an assistant professor at the Wayne State University School of Medicine, Department of Oncology. Her clinical and research interests are in molecular targeted therapy and immunotherapy in thoracic and head and neck malignancies, with a special focus in medical ethics. She serves as the site principal investigator (PI) for over 20 active clinical trials and enjoys collaborating with other PIs across the country and around the world.

Dr. Minna is Director of the Hamon Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at The University of Texas Southwestern Medical Center. He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. He graduated from Stanford Medical School where he did research with Dr. Leonard Herzenberg, was a resident at Massachusetts General Hospital, a Research Associate at the National Heart Lung and Blood Institute (under Dr. Marshal Nirenberg), Chief of the Section of Somatic Cell Genetics, Chief of the NCI-VA and then NCI-Navy Medical Oncology Branches at the National Cancer Institute (1975-1991). His work focused on understanding the molecular pathogenesis of lung cancer and translating this into the clinic. He has trained many investigators in lung cancer research, and led a joint Lung Cancer NCI Special Program of Research Excellence (SPORE) grant between UTSW and the MD Anderson Cancer Center and is part of NCI and Texas Cancer Prevention and Research Institute (CPRIT) multi-investigator grants to discover new therapeutic approaches and personalized medicine for lung cancer. He co-leads the Experimental Therapeutics Program for the UTSW Simmons Cancer Center.

Assistant Professor of Medical Oncology, whose translational research focus is on optimization of immunotherapeutic approaches for patients with oncogene-driven lung cancer

Thomas Marron MD PhD is the Assistant Director of Immunotherapy and Early Phase Trials at the Mount Sinai Hospital and an Assistant Professor of Medicine at Icahn School of Medicine. His primary interest is non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). As a member of the Tisch Cancer Institute and the Immunology Institute, he works closely with basic scientists across the Health System, working to translate pre-clinical findings into clinical trials, and conversely has also developed multiple window-of-opportunity trials which bring tissue, blood and stool back to the laboratory to study immunodynamic changes induced by novel immunotherapies. Dr. Marron is involved in dozens of industry-sponsored and investigator-initiated trials, with a focus on defining optimal combinatorial approaches to increase the response rates and durability of novel immune-based therapies, while limiting toxicity.

Dr. Mansfield is a medical oncologist at Mayo Clinic in Rochester, MN. He specializes in the treatment of thoracic malignancies and drug development. He is co-Director of Mayo Clinic's Precision Cancer Therapeutics program and runs a translational laboratory.

Dr. Hirva Mamdani is an Assistant Professor in the Department of Oncology at Karmanos Cancer Institute (KCI) /Wayne State University (WSU). She completed her Internal Medicine residency from Wayne State University and fellowship in Hematology and Oncology from Indiana University. She is a member of the Thoracic Oncology and Phase I Therapeutics Programs at KCI. Additionally, she is the Director of Lung Cancer Screening Program at KCI. Dr. Mamdani is involved in a number of clinical trial related to lung cancer treatment, including those focusing on immunotherapy and molecularly targeted therapies. Dr. Mamdani is a member of the American Society of Clinical Oncology (ASCO), Southwest Oncology Group (SWOG) Thoracic Working Group, Hoosier Cancer Research Network (HCRN) Thoracic Working Group, and American Cancer Society National Lung Cancer Roundtable. Dr. Mamdani’s areas of research interest include development of novel targeted therapies for NSCLC, mechanisms of resistance to immunotherapy, and strategies of targeting DNA damage response pathways in lung cancer.

Head, Thoracic and H&N cancer Therapeutics CTEP/NCI. worked at the FDA prior to joining NCI and served as Chief Center for Thoracic oncology at Georgetown Hospital for 7 years

Jia Luo, MD, is a fellow in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Luo received her medical degree at Stanford School of Medicine and completed residency and a chief residency year at Oregon Health & Science University. She is currently supported by an awarded Investigational Cancer Therapeutics T32 grant, and her work has been focused on developing tools to understand response to immunotherapy. She has first and co-authored papers in Cancer Discovery, Annals of Oncology, Nature Reviews Clinical Oncology, Clinical Cancer Research, and JCO: Precision Oncology. She developed an IIT at the AACR/ ASCO Methods in Clinical Cancer Research Workshop, and the work was supported by a Young Investigator Award from the Conquer Cancer Foundation of ASCO.

Christine M. Lovly, MD, PhD is currently an Associate Professor of Medicine at the Vanderbilt Ingram Cancer Center. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of cancer. Dr. Lovly has received grant funding from NIH/NCI, the American Cancer Society, the Damon Runyon foundation, the LUNGevity foundation, the GO2 foundation, the V Foundation, AACR, and LCFA/IASCL. She is an active member of ASCO, AACR, and IASLC. She is also an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Editorial Board for Cancer Discovery. Dr. Lovly is also an invited member of the Scientific Leadership Boards for the GO2 Foundation for Lung Cancer research, the LUNGevity foundation, and the Lung Cancer Research Foundation.